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Abstract Cushing syndrome due to ectopic secretion of ACTH in infants is rare. The 
treatment of choice is radical resection of the tumour in combination with pre-
operative chemotherapy using steroidogenesis inhibitors if necessary. If radical 
surgery is not possible, palliative treatment of hypercortisolemia is recommended. 
The most frequently used drug in infants is ketoconazole. Experience with the use 
of metyrapone is poor. We report an 8-month-old female infant with congenital 
immature sacrococcygeal teratoma secreting AFP, beta hCG and ACTH who had 
undergone non-radical resection of the tumour mass and was receiving standard 
risk chemotherapy (vinblastine, bleomycin, and cisplatin). The infant initially 
presented at the age of 6 months with ACTH-dependent Cushing syndrome 
(cortisol and ACTH level 325 ng/mL, 112 pg/mL respectively). Treatment with 
ketoconazole was initiated with a dose of 600 mg/day. Due to its ineffectiveness 
metyrapne was added in increasing dosages, up to 1,500 mg/day. In addition the 
schema of chemotherapy was changed (adriamycin, bleomycin, carboplatin), 
which resulted in normalization of cortisol levels and blood pressure. There were 
no metyrapone side effects during the treatment period. We can conclude that 
treatment with metyrapone at a dose of 1500 mg/day might be effective and safe 
in infants with Cushing syndrome. 
INTRODUCTION
Cushing syndrome (CS) due to ectopic secre-
tion of ACTH in infants is extremely rare and 
challenging to treat. The treatment of choice is 
radical resection of the ACTH secreting tumour 
with pre-operative pharmacological inhibition 
of steroidogenesis and chemotherapy if neces-
sary. If radical surgery is not possible, palliative 
treatment of hypercortisolemia is recommended. 
Inhibitors of steroidogenesis are difficult to use 
in this age group because data regarding effective 
dosage regimens is poor and there is no evidence 
of long-term safety and efficacy (Traina et al. 2013; 
Salunke et al. 2010). The most frequently used 
agent is ketoconazole. Experience with the use 
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of metyrapone in that age group is poor (Garge et al. 
2013). We report a case of a female infant with severe 
Cushing syndrome due to ectopic ACTH secretion by 
an immature sacrococcygeal teratoma. This is the first 
description of metyrapone use in severe CS due to ecto-
pic ACTH secretion in an infant.
CASE REPORT
A 8-month-old female infant was referred to the endo-
crinologist due to ACTH dependent CS. The patient 
was born at term to a G2 P2 mother by cesarean section 
with a birth weight of 4,280 g. The physical examine 
revealed anal atresia and a large tumour mass in the 
sacrococcygeal and pelvic region. Additional labora-
tory testing in the first days of life revealed a significant 
increase in alfafetoprotein (AFP) levels (59,000 ng/mL). 
At the age of 1 week, non radical resection of the tumor 
and the implantation of a colostomy were performed. 
The histopathological examination revealed a grade 3 
immature teratoma. After surgery AFP levels returned 
to normal but a CT scan confirmed residual tumour 
mass (27×21×28 mm). 
At the age of two months an increase in AFP and 
beta human chorionic gonadotropin (bata HCG) 
(379.5 ng/mL and 192 IU/L respectively) accompanied 
by an increase in tumour mass were found. Standard 
risk chemotherapy VBP (vinblastine, bleomycin, and 
cisplatin) was introduced. After 3 blocks of chemother-
apy there was no regression in tumor mass diameters. 
At the age of 4 months a rapid increase in appetite and 
subsequent body weight were noticed accompanied by 
a systematic increase in blood pressure. 
At the age of 6 months blood tests revealed 
elevated levels of cortisol and ACTH (325 ng/mL, 
112 pg/mL respectively). The schema of chemotherapy 
was upgraded to high risk VIP (high risk etosposid, 
ifosfamid, cisplatin), but there was still no regression in 
tumor mass and cortisol levels were increasing gradu-
ally up to 627 ng/mL Ketoconazole was introduced at 
the initial daily dose of 400 mg. Despite intensive hyper-
tensive treatment (metoprolol, captopril, aldacton), 
blood pressure was continuously increasing. The patient 
developed a hypertensive crisis with seizures and blood 
pressure at a maximum value of 210/160 mmHg. 
On admission to the Children’s University Hospi-
tal in Kraków at the age of 8 months, she presented in 
good general condition, with a body weight of 9 kg and 
blood pressure of 120/70 mmHg. Blood cortisol levels 
were high (739.8 ng/mL). The dosage of ketoconazole 
was increased to 600 mg without any significant effect 
on cortisol levels (699 ng/mL). At this point we decided 
to introduce metyrapone (125 mg twice a day). After 4 
days of treatment, cortisol levels returned to within the 
normal range (172 ng/mL). After four days of stabilility, 
a rapid increase in cortisol levels up to 700 ng/mL was 
found. Metyrapone was gradually increased to the max-
imum dose of 250 mg every 4 hours (1,500 mg per day). 
In addition, second line chemotherapy was introduced 
(ABK protocol: adriamycin, bleomycin, carboplatin). 
After 4 days of such treatment cortisol levels decreased 
to 132 ng/mL and remained stable. Appetite decreased 
as well and there was no increase in body weight. Blood 
pressure was normal (90/57 mmHg). During the whole 
treatment period we did not observe any metyrapone 
side effects. 
DISCUSSION
Ectopic secretion of ACTH by an immature teratoma 
is rare. There is one description of ACTH dependent 
CS due to immature sacrococcygeal teratoma in an 
adult female and one due to congenital immature tera-
toma in the region of the pituitary gland in an infant 
(Salunke et al. 2010; Moreno-Fernández et al. 2008). 
In the second case hypercortisolemia was successfully 
treated with ketoconazole at a dose of 200mg/day prior 
to the surgery (Salunke et al. 2010). On the contrary in 
this case a dose of 600 mg/day was not effective in the 
treatment of hypercortisolemia. 
For this reason we decided to use metyrapone as 
second line therapy. Metyrapone is an inhibitor of 
endogenous adrenal corticosteroid synthesis. It inhibits 
the enzyme responsible for the 11β-hydroxylation stage 
in the biosynthesis of cortisol and to a lesser extent, 
aldosterone. The major potential side effects reported 
in adult patients are hirsutism, acne and mineralocor-
ticoid effects (hypertension, hypokalemia and edema) 
(Feelders et al. 2010). 
An additional problem in pediatric patients is the 
dosage, because commercially available capsules con-
tain 250 mg of metyrapone and are not divisible. Metyr-
apone is occasionally used for short-term treatment of 
CS prior to surgery. Its efficacy in adults in the reduc-
tion of cortisol levels is about 75% (Traina et al. 2013; 
Feelders et al. 2010). 
Ketoconazole is an antifungal agent that, in higher 
dosages, reduces adrenal steroid production via inhibi-
tion of multiple steroidogenic enzymes. Data from ret-
rospective studies in adults show, that ketoconazole in a 
dose range between 400 and 1,200 mg/day can decrease 
cortisol production in about 70% of patients with CS 
(Feelders et al. 2010). 
There is no data regarding the efficacy of these this 
drug in infants, however it is the most frequently used 
inhibitor of steroidogenesis in this age group (Dutta et 
al. 2012) In the presented case the dose of 250 mg/day 
was initially effective, but after a short amount of time, 
cortisol levels increased and an increase of the dose up 
to 1,500 mg/day was needed. 
In addition second line chemotherapy was intro-
duced as well (ABK protocol adriamycin, bleomycin, 
carboplatin). The result was a decrease in cortisol levels 
to 94.2 ng/mL This is the first description of metyrapone 
treatment in an infant with CS due to ectopic secretion 
of ACTH. During the whole treatment period with 
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increasing doses of metyrapone (up to 1,500 mg daily) 
and regular monitoring of cortisol levels and blood 
pressure, no side effects of the drug were observed. 
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